Published in Neurosci Lett on April 27, 2001
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet (1989) 4.57
Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet (2001) 3.15
The effect of sodium chloride and temperature on the rate and extent of growth of Clostridium botulinum type A in pasteurized pork slurry. J Appl Bacteriol (1987) 2.91
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet (1994) 2.74
A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage (2003) 2.67
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol (2007) 2.47
Prevalence rates of dementia in an ageing population: are low rates due to the use of insensitive instruments? Age Ageing (1990) 2.45
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28
Predicting microbial growth: the consequences of quantity of data. Int J Food Microbiol (1989) 2.01
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet (2005) 1.94
Drugs for Alzheimer's disease. BMJ (2001) 1.92
Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology (2000) 1.85
A rapid method for preparing synaptosomes: comparison, with alternative procedures. Brain Res (1981) 1.85
Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2006) 1.83
Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet (1994) 1.77
The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry (2000) 1.61
Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology (2001) 1.59
Histochemical distribution of non-haem iron in the human brain. Acta Anat (Basel) (1992) 1.58
Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr (2001) 1.57
Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England. J Epidemiol Community Health (1995) 1.53
Genomic diversity correlates with clinical variation in Ph'-negative chronic myeloid leukaemia. Nature (1986) 1.53
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain (1999) 1.48
Cutting needle biopsy in the diagnosis of clinically suspected non-carcinomatous disease of the lung. Br J Radiol (2000) 1.47
Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage (2002) 1.44
Purification and characterization of two soluble Cl(-)-activated arginyl aminopeptidases from human brain and their endopeptidase action on neuropeptides. J Neurochem (1988) 1.41
No evidence of an association between the T16189C mtDNA variant and late onset dementia. J Med Genet (2004) 1.40
Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology (2004) 1.38
Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology (2007) 1.38
School attendance as a factor in deliberate self poisoning by 12-15 year old adolescents. BMJ (1992) 1.38
Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet (1986) 1.35
Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology (2001) 1.34
Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology (2001) 1.32
Cognitive performance in hypertensive and normotensive older subjects. Hypertension (2000) 1.31
Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol (2004) 1.30
Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry (2002) 1.28
Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology (2005) 1.28
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci (1991) 1.24
The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia. Hum Mol Genet (1998) 1.23
Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. Neurology (2000) 1.22
Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry (2006) 1.21
Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res (1997) 1.20
Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord (2002) 1.20
MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology (2000) 1.19
Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord (2000) 1.18
Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol (1998) 1.17
Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology (1999) 1.16
Does the mitochondrial genome play a role in the etiology of Alzheimer's disease? Hum Genet (2006) 1.16
Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology (2000) 1.14
Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut (2005) 1.11
Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord (1993) 1.11
Telomeric association of chromosomes in B-cell lymphoid leukemia. Hum Genet (1984) 1.10
Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype. J Neurol Neurosurg Psychiatry (2008) 1.08
Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience (1995) 1.08
Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol (2006) 1.08
Depression with late onset is associated with right frontal lobe atrophy. Psychol Med (2003) 1.05
Do experienced diagnosticians agree about the diagnosis of dementia from survey data? The effects of informants' reports and interviewers' vignettes. Int J Geriatr Psychiatry (1998) 1.05
Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage (2003) 1.05
A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord (2001) 1.05
The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2005) 1.05
Agonal status affects the metabolic activity of nerve endings isolated from postmortem human brain. Neurochem Pathol (1985) 1.03
The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatr Psychiatry (2001) 1.02
Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience (1998) 1.02
Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport (1994) 1.01
5HT2 receptor changes in major depression. Biol Psychiatry (1990) 1.00
Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. Biochem J (1992) 0.99
Matching-to-sample deficits in patients with senile dementias of the Alzheimer and Lewy body types. Arch Neurol (1992) 0.99
Metabolically active synaptosomes can be prepared from frozen rat and human brain. J Neurochem (1983) 0.99
Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neurosci Lett (2000) 0.99
Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience (2000) 0.98
Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement? Cancer Genet Cytogenet (1991) 0.98
The pituitary-adrenal system of the genetically obese (ob/ob) mouse. J Endocrinol (1975) 0.97
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord (2001) 0.97
Uptake and distribution of iron and transferrin in the adult rat brain. J Neurochem (1992) 0.97
Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry (1987) 0.96
Gastrointestinal absorption of aluminium in Alzheimer's disease: response to aluminium citrate. Age Ageing (1992) 0.96
Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry (2001) 0.95
Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2006) 0.95